Bruker Corp
NASDAQ:BRKR
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Bruker Corp
NASDAQ:BRKR
|
5.5B USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
191.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
152.7B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
79.2T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
34.2B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
294.7B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
35.4B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.2B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.8B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
163.2B HKD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Bruker Corp
Glance View
Bruker Corporation, a prominent entity in the analytical instrumentation sector, traces its roots back to Germany. Wholly devoted to advancing science and industry through meticulous precision, Bruker has carved out a niche in creating sophisticated analytical instruments that enable comprehensive research and diagnostics. Their portfolio spans a diverse range of technologies, including mass spectrometry, magnetic resonance imaging, X-ray analysis, and molecular spectroscopy, all meticulously designed to meet the exacting demands of their clientele. These sophisticated tools empower researchers, scientists, and industrial operators to obtain insights into the fundamental properties of materials and substances, thereby driving forward discoveries in medicine, chemistry, and material science. Bruker's financial health rests on a business model grounded in both innovation and strategic expansion. They generate revenue through the sale of their high-precision instruments as well as a steadily growing service segment that ensures their equipment remains at the cutting edge of functionality and reliability. Additionally, the company pursues collaborative ventures with academic institutions and industrial partners, creating a synergistic loop for product and market development. This strategic approach not only fortifies their market position but also nurtures long-term relationships, underpinning recurring revenues from service contracts and incremental technology upgrades. With a clear focus on driving quality and innovation, Bruker Corporation thrives in a competitive landscape, catering to the evolving needs of scientific discovery and industrial precision.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Bruker Corp is 48%, which is below its 3-year median of 50.1%.
Over the last 3 years, Bruker Corp’s Gross Margin has decreased from 51.2% to 48%. During this period, it reached a low of 48% on Sep 30, 2025 and a high of 51.9% on Mar 31, 2023.